Empiric treatment with aspirin and ticagrelor is the most cost-effective strategy in patients with minor stroke or transient ischemic attack

Abstract excerpt

<h4>Background</h4> Patients with minor ischemic stroke or transient ischemic attacks (TIAs) are often treated with dual antiplatelet therapy regimens as part of secondary stroke prevention. Clopidogrel, an antiplatelet used in these regimens, is metabolised into its active form by the CYP2C19 enzyme. Patients with loss of function (LOF) mutations in CYP2C19 are at risk for poorer secondary outcomes when prescribe...

Topics

Open a Topic to create a Post that cites this publication.

• Clopidogrel
• Cost-Benefit Analysis
• Decision Trees
• Ischemic Attack, Transient
• Markov Chains
• Placebos
• Platelet Aggregation Inhibitors
• Quality-Adjusted Life Years

Identifiers and source

Literature Corpus work

4d24e872-dd13-5467-80c0-1331fd204393

DOI

10.1101/2023.05.16.23290069